Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — 23rd Annual Needham Virtual Growth Conference (January 2021)
29 slides from Angiodynamics's conference presentation, Jan 11, 2021
Slide 1: 23rd Annual Needham Virtual Growth Conference
01 | 11 | 2021 ANGIODYNAMICS 23rd Annual Needham Virtual Growth Conference Jim Clemmer, President & CEO
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 4: Focused Transformation: U.S. Total Addressable Markets
4 FOCUSED TRANSFORMATIONU.S. Total Addressable Markets Our strategic initiative to become a growth company begins 2018 Launch of the Auryon System gives us access to the peripheral atherectomy market New Thrombectomy & NanoKnife System portfolio additions & indications increase market access $1.3B 0
Slide 5: Product portfolio: invest for growth and maintain positioning
5 Diagnostic Catheters, Guidewires and Kits Vascular Access Catheters and Accessories Microwave & Radiofrequency Tumor Ablation Endovenous Laser Treatment Lung Biopsy Safety Radiation Treatment Stabilization Balloons INVEST FOR GROWTH MAINTAIN POSITIONING Thrombus Management Irreversible Electropora
Slide 6: Focused Investment
6 FOCUSED INVESTMENT Healthy Blood Flow to the Heart Expanded Treatment Options in Oncology Leveraging 3 main drivers to carve out our space in large, growing markets through innovative, disruptive technologies that treat patients with cancer, promote healthy blood flow and deliver critical therapie
Slide 7: Peripheral Atherectomy
PERIPHERAL ATHERECTOMY 01 | 11 | 2021
Slide 8: Auryon System catheters and laser technology
2.35 mmAspiration and Off-Center capabilities and indicated for Peripheral Atherectomy and In-Stent Restenosis (ISR) 2.0 mmAspiration capability and indicated for Peripheral Atherectomy and ISR 1.5 mmIndicated for Peripheral Atherectomy Why wavelength mattersEach type of tissue interacts differently
Slide 9: Peripheral Atherectomy: US Addressable Markets & Competitive Landscape
PERIPHERAL ATHERECTOMYUS Addressable Markets & Competitive Landscape MECHANICAL LASER $555M 23%1 1. Peripheral Vascular Devices Medtech 360 Market Analysis US 2017. (2016, December). Millennium Research Group, Inc. 77%1 2020 Total Addressable Market (TAM) 9 Company Product Thrombus Plaque Fibrotic I
Slide 10: Peripheral Atherectomy: Continuing our momentum of growth
10 PERIPHERAL ATHERECTOMYContinuing our momentum of growth PRODUCT DEVELOPMENT Product development pipelinePortfolio and product indication expansionContinuous voice of customer CLINICAL COMPENDIUMExpand awareness by creating a strong podium and clinical publication presence Clinically differentiate
Slide 11: Thrombus Management
THROMBUS MANAGEMENT 01 | 11 | 2021
Slide 12: Deep Vein Thrombosis and Pulmonary Embolism
12 Deep Vein ThrombosisDVT + Pulmonary EmbolismPE = Venous ThromboembolismVTE A blood clot that forms in a deep vein, usually the leg, groin or arm A DVT breaks free from a vein wall and travels to the lungs blocking some or all of the blood supply DVT and PE are collectively referred to as VTE 208,
Slide 13: DVT & PE Treatment Options
13 DVT & PE TREATMENT OPTIONSPercutaneous Thrombectomy CDT & US-CDTCatheter-Directed Thrombolysis (with or without the assistance of ultrasound) PCMTPharmacomechanical Thrombectomy AngioVacContinuous Aspiration Suction Thrombectomy MTMechanical Retrieval Thrombectomy MAMechanical Aspiration(Small &
Slide 14: Thrombus Management: Purpose Built Portfolio & Technology
THROMBUS MANAGEMENTPurpose Built Portfolio & Technology 14 Right Heart AngioVac’s use is currently focused on the Right Heart, which is a $77M addressable market. Pulmonary Embolism Deep Vein Thrombosis A multi-purpose mechanical aspiration device will allow us to compete in the broader DVT & PE add
Slide 15: The AngioVac System Difference
The Difference The AngioVac System allows for the continuous aspiration of embolic material such as fresh, soft thrombi or vegetation from the venous systemUtilizing a self-expanding, nitinol reinforced funnel tipSimultaneously reinfusing the patient’s own filtered blood to limit procedural blood lo
Slide 16: Planned Portfolio Additions & U.S. Addressable Markets Expansion
THROMBUS MANAGEMENTPlanned Portfolio Additions & U.S. Addressable Markets Expansion 16 $1.3B $1.6B FY 2021 FY 2022 FY 2023 FY 2025 FY 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 $140M $700M $3.6B $1.5B 1 2 The planned portfolio additions are not guarantees of future performance
Slide 17: Irreversible Electroporation
IRREVERSIBLE ELECTROPORATION 01 | 11 | 2021
Slide 18: Irreversible Electroporation: NanoKnife
18 Probe placement Placement of probes around a target area provides effective treatment coverage a-d Electrical pulses cause pores to form within the cellular membrane leading to non-thermal cell death a-d Electrical field Decellularization Non-thermal Revascularization The NanoKnife System’s uniqu
Slide 19: NanoKnife Provides Innovation Doctors Need
19 Localized Treatment Strong safety profile Maintains potential for future treatments Provides options for patients NANOKNIFE PROVIDES INNOVATIONDOCTORS NEED Spares critical structures and nerves Treated tissue can revascularize Preserves patient's quality of life Non-thermal energy decellularizes
Slide 20: DIRECT Study and Prostate IDE
20 DIRECT StudyThis study is evaluating the use of the NanoKnife System as a potential treatment for stage III pancreatic cancer. Prostate IDEThis safety study will evaluate the use of the NanoKnife System as a focal therapy option for prostate tissue. Liver Oral Cavity Pancreas Kidney Bladder Melan
Slide 21: Prostate Cancer Focal Therapy: Clinical Expansion
21 Focal therapy bridges the gap between whole gland treatment and active surveillance in an attempt to maximize quality of life by avoiding the effects of whole gland radiation or surgery.However…adoption remains low (<5%) due to gaps within existing technology. 27% will undergo radiotherapy of whi
Slide 22: NanoKnife Platform: Expanding Indications and Reimbursement
22 The Team Expanding Indications Pancreas pivotal study underway (DIRECT)Prostate safety study underwayFDA Pre-Sub meeting regarding prostate tissue indication complete InpatientICD-10 Code (2018)DRGs (2019)Organ Agnostic CPT Code (2020)OutpatientOutpatient (2021)ASC (2021) ExpandedReimbursement NA
Slide 23: Vascular Access
pe VASCULAR ACCESS ®D angiodynamics
Slide 24: Vascular Access: Safely delivering medication to patients
24 VASCULAR ACCESSSafely delivering medication to patients PORTFOLIO MARKET ACCESS PERFORMANCE PICCs Midlines Tip Location Ports Dialysis Point of Care Ultrasound Delivering on our product road map including development of an integrated navigation & tip location technology that enables the use of ou
Slide 25: First Half FY2021 Highlights
First Half FY2021 Highlights $ in Millions (except per share data) 1H FY2021 1H FY2020 YOY Change Revenue $143.0M $136.0M 5.1% Gross Margin 53.1% 58.6% (550 bps) Adjusted EPS $0.03 $0.14 ($0.11) Adjusted EBITDA $9.6 $13.7 $4.1 Free Cash Flow $2.8 ($4.6) $7.4 Financial Performance FY 2021 Guidance (U
Slide 26: Strategic Transformation
PURSUIT OF LARGER MARKETSActive portfolio management enables us to compete in larger, growing markets relying on technology & innovation to produce measurable patient outcomes FOCUSED RESOURCE DEVELOPMENTResource deployment is focused in areas that offer best opportunities for success PORTFOLIO TRAN
Slide 27: | | 2021 ANGIODYNAMICS Jim Clemmer, President & CEO
01 | 11 | 2021 ANGIODYNAMICS Investor Presentation Jim Clemmer, President & CEO
Slide 28: Peripheral Atherectomy References
28 **Peripheral Atherectomy References: a. Rundback J, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Novel laser-based catheter for peripheral atherectomy: 6-month results from the Eximo Medical B-Laser™ IDE study. Catheter Cardiovasc Interv. 2019;1-8. b. Shammas NW, Chandra P, Bro
Slide 29: AngioVac Indications for Use and Contraindications
AngioVac Cannula Indication for Use: The AngioVac Cannula is indicated for use as a venous drainage cannula and for removal of fresh, soft thrombi or emboli during extracorporeal bypass for up to 6 hours. | Contraindications: Contraindicated for patients with severe arterial or venous vascular disea
AngioDynamics — 23rd Annual Needham Virtual Growth Conference (January 2021) on 6ix